Shares of Neurocrine Biosciences NBIX rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 13.33% year over year to $0.91, which beat the estimate of $0.54.
Revenue of $247,900,000 rose by 1.56% from the same period last year, which missed the estimate of $262,400,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 04, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1046/39561
Recent Stock Performance
52-week high: $136.26
52-week low: $72.14
Price action over last quarter: Up 30.79%
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
